These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 12008197

  • 1. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
    van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J.
    Eur J Cancer; 2002 May; 38(8):1090-9. PubMed ID: 12008197
    [Abstract] [Full Text] [Related]

  • 2. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
    van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J.
    Clin Cancer Res; 2000 Apr; 6(4):1365-71. PubMed ID: 10778964
    [Abstract] [Full Text] [Related]

  • 3. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
    van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A.
    Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
    [Abstract] [Full Text] [Related]

  • 4. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E, de Valeriola D, Kerger J, Bleiberg H, Kusenda Z, Brassinne C, Bartholomeus S, Selleslags J, Hennebert P, Wythouck H, Cazenave I, Lefresne-Soulas F, Piccart M.
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [Abstract] [Full Text] [Related]

  • 5. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
    Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):72-8. PubMed ID: 15316750
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
    Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulias V.
    Anticancer Res; 2003 Jan; 23(1B):785-91. PubMed ID: 12680184
    [Abstract] [Full Text] [Related]

  • 8. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA.
    Cancer Chemother Pharmacol; 2000 Jan; 46(6):442-8. PubMed ID: 11138457
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study.
    Schrijvers D, Pronk L, Highley M, Bruno R, Locci-Tonelli D, De Bruijn E, Van Oosterom AT, Verweij J.
    Am J Clin Oncol; 2000 Aug; 23(4):358-63. PubMed ID: 10955864
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
    Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C.
    J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
    Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, Osterwalder B, Verweij J, Twelves C.
    Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
    Giannakakis T, Kakolyris S, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulias V.
    Anticancer Res; 2002 Jul; 22(6B):3743-8. PubMed ID: 12552987
    [Abstract] [Full Text] [Related]

  • 19. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH, Jones CB, Garrison M, Patnaik A, Takimoto C, McCreery H, Skinner M, Tolcher AW, Rowinsky EK.
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
    Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH.
    J Clin Oncol; 2000 Sep 15; 18(18):3288-94. PubMed ID: 10986062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.